- alotti c
- Stallings E
- Punnett m
- et al.
Based on previous experience with vaccines during pregnancy, and without putative mechanisms of fetal harm, similar efficacy and side effects in the non-pregnant population were expected with vaccination against SARS-CoV-2 during pregnancy. Existing data, albeit limited, supports this; No major safety signals were observed in animal reproductive toxicology studies or with post-marketing surveillance. However, until recently, there was little consensus regarding routine vaccination during pregnancy, and vaccination frequency in pregnant women remains high.
- skgift m
- Najrbol m
- Akigo or
- et al.
- Calafat E
- Maggie Los Angeles
- From Dadelszen P.
- O’Brien B
- Khalil A
and temporally, as well as the relative paucity of trial data in this population. However, the average benefits of vaccination can be weighed against the average risks. As a general principle, vaccination of pregnant women should only be recommended if the required number of vaccination (NNV) to prevent maternal and fetal infection with COVID-19 is less than the NNV to cause harm.
Real-life estimates of NNV for pregnant women are likely to be lower (i.e. better) than those estimated here based on increasing cumulative rates of SARS-CoV-2 infection over time, particularly among unvaccinated individuals, and prevalence of SARS-CoV-2 virus provocative variables. to worry. Also, pregnant women may have young children or live with other young children who are unlikely to receive the COVID-19 vaccination but likely to come into contact with others at activities and daycare.
The balance of risks favors vaccination against COVID-19 during pregnancy, especially to avoid severe maternal infection, premature birth or caesarean section. This data should be used to address and avoid vaccine frequency driven by knowledge gaps.
PO’B is co-chair of the Royal College of Obstetricians and Gynecologists’ Vaccine Committee. EM received grants from Gedeon Richter, Chugai Pharma, and Kebomed, and was a consultant to Pfizer in 2018. AK is a member of the COVAX working group and principal investigator for the PregCov trial and the Pfizer COVID vaccine trial. PH is the principal investigator for the PregCov trial. All authors are leading and collaborating on COVID-19 vaccine studies.
Clinical features, risk factors, and maternal and perinatal outcomes of 2019-nCoV during pregnancy: a live systematic review and meta‐analysis.
BMJ. 2020; 370m3320
Acceptance of the COVID-19 vaccine among pregnant women and mothers of young children: survey results in 16 countries.
Eur J Epidemiol. 2021; 36: 197-211
The SARS-CoV-2 vaccine during pregnancy: a unique opportunity for equity.
Lancet. 2021; 398: 951
date of publication
Published: 02 November 2021
© 2021 Elsevier Ltd. all rights are save.
Access this article on ScienceDirect